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Abstract Methyl CpG binding protein-2 (MeCP2) is an
essential epigenetic regulator in human brain development.
Rett syndrome, the primary disorder caused by mutations in
the X-linked MECP2 gene, is characterized by a period of
cognitive decline and development of hand stereotypies and
seizures following an apparently normal early infancy. In
addition, MECP2 mutations and duplications are observed
in a spectrum of neurodevelopmental disorders, including
severe neonatal encephalopathy, X-linked mental retardation,
and autism, implicating MeCP2 as an essential regulator of
postnatal brain development. In this review, we compare the
mutation types and inheritance patterns of the human
disordersassociatedwithMECP2. In addition, we summarize
the current understanding of MeCP2 as a central epigenetic
regulator of activity-dependent synaptic maturation. As
MeCP2 occupies a central role in the pathogenesis of
multiple neurodevelopmental disorders, continued investiga-
tion into MeCP2 function and regulatory pathways may
show promise for developing broad-spectrum therapies.
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Introduction
The MECP2 gene encodes methyl CpG binding protein-2
(MeCP2), a transcriptional regulator required for proper
neuronal development. Mutations in MECP2 are the major
cause of the neurodevelopmental disorder Rett syndrome
(RTT), an X-linked disorder that primarily affects females.
MECP2 mutations and dysfunctions have also been associ-
ated with a broad array of other neurodevelopmental
disorders in males and females, including X-linked mental
retardation (XLMR), severe neonatal encephalopathy, Angel-
man’s syndrome (AS), and autism, demonstrating that
disruption of MeCP2 can have wide-ranging effects on
neurodevelopment and lead to a spectrum of disorders [1].
However, the extent of MECP2 mutations within these
individual disorders is variable. Although MECP2 mutations
can account for up to 96% of classic RTT [2], they are rare in
other disorders (eg, autism), indicating that MECP2 is just
one of many genes that could contribute to the broader
spectrum of neurodevelopmental phenotypes. Additionally, a
clear correlation does not always exist between specific
MECP2 mutations and individual disorders or phenotypic
severity, suggesting that genetic, epigenetic, and/or environ-
mental factors interact with the MECP2 mutation to
determine the final phenotypic outcome in terms of type
and severity of the disorder.
MECP2 mutations can be grouped into three general
categories: severe loss-of-function mutations, mild loss-of-
function mutations, and a broad group of duplications and
other noncoding mutations that affect MeCP2 expression
levels. Each mutation type is associated with a subset of
disorders (Fig. 1). The involvement of MeCP2 in multiple
neurodevelopmental disorders demonstrates that it occupies
a central role in the postnatal development of the human
brain. Understanding the role that MeCP2 plays in brain
development and maturation is important for understanding
the pathogenesis of these disorders and identifying potential
therapeutic targets. To achieve this will require a thorough
understanding of the molecular mechanisms through which
MeCP2 acts, as well as how MeCP2 interacts with
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MECP2 Inheritance and X Inactivation
MECP2 is located on the X chromosome. As such, it is
s u b j e c t e dt oa nX - l i n k e di n h eritance pattern. Females
inherit two X chromosomes, one maternal and one paternal,
whereas males inherit their single X chromosome mater-
nally. Therefore, whereas females can inherit MECP2
mutations from either parent, male inheritance of MECP2
mutations is exclusively maternal. This has dramatic effects
on the transmittance of MECP2 mutations as well as the
stratification of MECP2-associated disorders by gender
(Table 1). The MECP2 gene is also subject to X-
chromosome inactivation (XCI) in females. XCI is the
process by which one of the two X chromosomes carried by
females is inactivated to achieve gene expression patterns
similar to those found in males, who carry only one copy of
the X chromosome. XCI occurs on a cell-by-cell basis and
is a predominantly random process. However, extreme
degrees of skewing can occur with preferential inactivation
of the maternal or paternal X chromosome. Therefore, the
phenotypic results of MeCP2 mutations in females are
likely not only based on the type of mutation but also on
the degree of inactivation between the mutant and wild-type
alleles. With a single X chromosome, males are more
severely affected by MECP2 mutations than females, who
along with the mutant gene on one X chromosome carry a
normal copy of MECP2 on the other.
MECP2 mutations are mostly sporadic, occurring pref-
erentially as C>T transitions of CpG dinucleotides and
preferentially on the paternal X chromosome [3, 4]. It has
been postulated that the low number of males with MECP2
mutations is the result of a lethal in utero effect of having
no functional MECP2 from their single X chromosome.
However, the predominantly paternal origin of MeCP2
mutations likely prevents them from being transmitted to
male offspring in the first place.
MeCP2 and Neurodevelopmental Disorders
Rett Syndrome
MeCP2 dysfunction is associated with several neurodeve-
lopmental disorders. The primary neurodevelopmental
disorder associated with MECP2 mutations is RTT, which
affects about 1 in 15,000 females [5]. Classic RTT is
characterized by apparently normal early development for the
first 6 to 18 months of life followed by a period of
developmental regression and loss of acquired skills that
results in intellectual disability (ID), loss of speech and
purposeful hand movements, ataxia, seizures, and respiratory
abnormalities.ThereareseveralrecognizedvariantsofRTTin
Fig. 1 Association of neurodevelopmental disorders with specific
classes of Methyl CpG binding protein-2 (MeCP2) mutation. The
schematic diagram depicts the major MeCP2-based neurodevelop-
mental disorders and their association with each class of MeCP2
mutation. RTT—Rett syndrome; XLMR—X-linked mental retardation
Table 1 Neurodevelopmental disorders associated with MeCP2 mutations
Studies Disorder Mutation Gender Parent of
origin
Amir et al. [5] Rett syndrome Severe loss of function Female Paternal
Schanen et al. [8], Villard et al. [9] Severe neonatal encephalopathy Severe loss of function Male Maternal
Carney et al. [21] Autism Severe loss of Function Female Paternal (?)
Couvert et al. [18] X-linked mental retardation Mild loss of function Male Maternal
Lugtenberg et al. [19•] X-linked mental retardation Duplication Male Maternal
Loat et al. [22], Nagarajan et al. [23],
Shibayama et al. [24], Ramocki et al. [25••]
Autism Duplication/noncoding
variants
Male Maternal
Adegbola et al. [27], Cohen et al. [28],
Watson et al. [29]
Other Severe/mild Male/female Either (?)
MeCP2 methyl CpG binding protein-2
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onset seizure, and preserved speech variants, which have
similar yet distinct clinical phenotypes from classic RTT.
About 96% of classic RTT cases are associated with MECP2
mutations [2], whereas other forms are largely associated
with other genetic mutations, such as CDKL5 in the early-
onset seizure variant [6]a n dFOXG1 mutations in the
congenital variant [7•]. Thus, whereas MECP2 mutations
are clearly responsible for most classic RTT, they are not the
only genetic lesion that can yield RTT phenotypes.
Significant phenotypic variability exists in classic RTT,
even among individuals with the same MECP2 mutation.
Skewed XCI has been used to explain the mild phenotype
associated with rare maternal carriers of MECP2 mutations
[8, 9]. In addition, three different Mecp2-deficient murine
models showed variably skewed XCI favorably inactivating
the mutant allele and correlating with phenotypic severity
[10, 11]. However, most girls with classic RTT show
random X chromosome inactivation patterns [12]. Further-
more, recent studies have questioned the exclusive ability
of XCI status to explain discordance between individuals
with identical MECP2 mutations but different severity,
suggesting the influence of genetic modifiers [13•, 14•].
Severe Neonatal Encephalopathy
The classic RTT phenotype in males is exceedingly rare
and associated with a 47,XXY karyotype or somatic
mosaicism for an MECP2 mutation [15, 16]. Both of these
situations recapitulate the female scenario of XCI and allow
for expression of some wild-type MECP2. In karyotypically
normal boys, RTT-associated MECP2 mutations present as
severe neonatal encephalopathy, a disorder characterized by
a static encephalopathy, severe developmental delays,
hypotonia, seizures, and respiratory abnormalities that often
leads to death at an early age [8, 9]. Most of these
individuals inherited the MECP2 mutation from mildly or
unaffected mothers with favorable XCI skewing [8, 9].
Because XCI of the mutant MECP2 allele is random in
most females, favorably skewed maternal carriers of RTT-
associated mutations are rare. Therefore, the prevalence of
severe neonatal encephalopathy caused by MECP2 muta-
tions is also thought to be rare. However, most boys with
this disorder have been identified because they have female
siblings with RTT. It is possible that more cases exist outside
of known RTT families that have yet to be identified.
X-linked Mental Retardation
XLMR is a source of inherited ID affecting 1 in 600 to 1 in
1000 males, as well as a smaller—but still significant—
number of females [17]. XLMR is a genetically diverse
disorder arising from mutation or duplication of genes
across the X chromosome, including MECP2. In early
studies, MECP2 point mutations were identified in up to
2% of individuals with XLMR [18]. In males, these
mutations result in severe ID, speech impairment, and
motor abnormalities—including progressive spasticity—
whereas females display mild ID or appear unaffected. To
date, XLMR-associated MECP2 mutations have not been
identified in RTT or severe neonatal encephalopathy; also,
RTT mutations have not been found in cases of XLMR.
Duplications in Xq28, a region of the X chromosome that
includes MECP2, also have been implicated in 1% to 2% of
XLMR cases [19•]. Analysis of these duplications in
multiple XLMR families has identified a region containing
MECP2 and its neighbor IRAK1 as the minimal genomic
region associated with XLMR and Xq28 duplications [19•].
MECP2 duplication syndrome is characterized by severe
ID, lack of speech, progressive spasticity, and susceptibility
to respiratory infections in males and mildly affected or
unaffected females. The molecular situation arising from
MECP2 duplication is very different from that caused by
MECP2 mutations in XLMR. Whereas mutations are
thought to cause neurodevelopmental disorders through
reduced levels of functional MeCP2, MeCP2 duplications
actually result in elevated MeCP2 levels [20]. That both
under- and overexpression of functional MeCP2 can lead to
neurodevelopmental disorders serves to highlight the
requirement for correct regulation of MeCP2 expression
for proper neuronal development.
Female carriers of XLMR MECP2 mutations generally
show balanced XCI, signifying that XLMR mutations are
less severe compared with those that result in RTT.
Alternatively, MECP2 duplication carrier females display
extreme XCI skewing (85%–100%) favoring inactivation of
the duplicated allele [20]. This suggests that the effects of
MECP2 duplication are more severe than those of the
XLMR mutations and that the mild phenotype in these
females is due to preferential inactivation of the duplicated
allele. Both the relatively mild nature of XLMR mutations
in females and the preferential XCI skewing of duplications
allow for maternal transmission of defective MECP2 alleles
to male and female offspring [19•, 20], a situation that is
not possible with the more severe RTT mutations. Because
of this, MECP2 mutations associated with XLMR are much
more common in males than those associated with RTT.
Autism
Autism and RTT have significant phenotypic overlap, and
both are classified as pervasive developmental disorders.
Although autism and RTT have a strong genetic compo-
nent, the genetic basis of autism is unclear and likely
involves multiple genes. Mutations in MECP2 identical to
some classic RTT mutations have been identified in a small
Curr Psychiatry Rep (2010) 12:127–134 129number of autistic females who do not meet the diagnostic
criteria for RTT [21]. In addition to discrete MECP2
mutations, linkage analysis has identified the over- and
undertransmittance of specific MECP2 variants in families
with autistic children, suggesting a link between MECP2
and increased susceptibility to autism [22]. Reduced
expression of MeCP2 protein frequently occurs in the
frontal cortex of autistic individuals and is correlated with
increased MECP2 promoter methylation [23]. Decreased
MeCP2 expression may also be caused by variations in 3
regulatory elements of MECP2, which are found more
commonly in autistic individuals than in controls [24].
Finally, a recent study found a high comorbidity of autism
in males with MECP2 duplications inherited from maternal
carriers with neuropsychiatric symptoms [25••]. Therefore,
as with XLMR, over- and underexpression of MeCP2 can
lead to an autistic phenotype in some individuals.
Autism is relatively rare in girls, making the association
of MECP2 mutations in girls with an autistic phenotype
particularly interesting. Because of the phenotypic overlap
between RTT and autism, as well as the phenotypic
variability between individuals in both disorders, it is not
clear if an MECP2 mutation with an autism diagnosis is a
different disorder than RTT, or if the two are simply
different representations on a spectrum associated with
MECP2 mutations. It was reported that an initial diagnosis
of autism in girls with MECP2 mutations was not
maintained as they grew older, and it was suggested that
the autistic phenotype may actually represent an RTT
variant [26]. Regardless of whether another autistic pheno-
type associated with MECP2 mutations is truly autism, it is
likely that the phenotypic differences from RTT or XLMR
arise from differences in genetic background and environ-
mental exposures in each affected individual.
Other Disorders
MECP2 mutations also have been reported in other
neurological cases. A father and daughter were identified
with a mild neurobehavioral phenotype including cognitive
and motor difficulties. Both carry a proline-to-alanine point
mutation at amino acid 152 in MeCP2, and the daughter
displays balanced XCI, suggesting that this mutation has a
mild effect on MeCP2 function [27]. It is interesting to note
that a different mutation at the same site (proline to arginine)
is commonly found in classic RTT. The arginine mutation has
a much more dramatic effect on the biochemical properties of
MeCP2 than does the alanine mutation, which is likely
related to the differences in phenotypic severity between the
two mutations [27]. Another report described a boy with
early-onset schizophrenia and developmental receptive lan-
guage disorder with a mutation in MECP2 [28]. This same
mutation is found in XLMR but presents with a vastly
different phenotype in this case. Cases of AS with MECP2
mutations also have been reported [29]. AS is a neuro-
developmental disorder with some phenotypic similarities to
RTT but with an earlier onset characterized by hypotonicity
at birth. AS is primarily caused by deletions, mutations, or
imprinting errors of the UBE3A gene on chromosome 15,
but 15% of AS cases have no identified genetic abnormality
at this site. Several different MECP2 mutations, most of
which are also found in RTT, have been found in boys and
girls diagnosed with AS. Some individuals transitioned to a
more RTT-like phenotype with age, whereas others main-
tained an AS-like phenotype. The appearance of MECP2
mutations usually associated with other disorders in these
cases is another demonstration of variable expressivity. In
these cases, rare genetic variants and/or environmental
insults may interact with the MECP2 mutations to produce
the uncommon phenotypes described previously. Therefore,
not only is there extensive variability of phenotypes
associated with single mutations within specific disorders,
but the capacity also exists for specific mutations to give rise
to distinct disorders in different individuals.
MeCP2 Function
MeCP2 is a member of a family of proteins that specifically
bind to methylated DNA sequences in the genome. DNA
methylation is a covalent modification to CpG dinucleo-
tides and an epigenetic mark used by cells to alter
expression of genes without permanently changing the
DNA sequence. In this way, DNA methylation represents a
mitotically heritable yet reversible modification to the
genome. By binding to methylated DNA, MeCP2 can read
these epigenetic marks in the genome and translate them
into functional effects of modified gene expression.
Historically, DNA methylation has been thought to be a
repressive mark, primarily when found at CpG-rich gene
promoters. Therefore, MeCP2 was predicted to be a global
repressor of transcription of genes by binding to methylated
gene promoters and recruiting transcriptional repressors to
silence gene expression [30]. However, gene promoters are
vastly de-enriched for DNA methylation, and global
analyses of MeCP2-dependent expression have not yielded
many clear target genes with densely methylated promoters
that require MeCP2 for silencing, suggesting that the
function of MeCP2 is broader than the proximal repression
of methylated gene promoters. Recently, new models of
MeCP2 function have been proposed in which MeCP2 acts
as a transcriptional modulator capable of regulating
increases and decreases in expression of transcriptionally
active genes by long-range regulation of chromatin struc-
ture from distal methylation sites outside of gene promoters
[31, 32•]. An additional study suggested an activating role
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CREB at the promoters of active genes [33•].
Many gene targets of MeCP2 undergo rapid changes in
expression following activity-dependent neuronal activa-
tion. In the case of the MeCP2 target gene BDNF, this is
achieved through activity-dependent phosphorylation of
MeCP2 [34]. By acting as an activity-dependent regulator
of gene expression, MeCP2 is positioned to integrate
signals from neuronal activation and epigenetic marks to
control the expression of its target genes. It is likely that the
heterogeneous nature of activity-dependent activation and
epigenetic status of individual neurons or neuronal net-
works in the maturing brain have led to the inability to fully
delineate the entire spectrum of MeCP2 target genes.
MeCP2 is ubiquitously expressed in human tissues, but
particularly high protein levels are found in the brain [35].
Within the brain, neurons contain the highest levels of
MeCP2, but expression in these cells is heterogeneous and
based primarily on the maturational state of the individual
neurons. The level of MeCP2 in neurons is initially low and
increases over the course of postnatal neuronal develop-
ment, reaching a maximum in a subpopulation of mature
postmitotic neurons [36]. This pattern of expression
suggests that MeCP2 is involved in the maturation of
existing neurons rather than the development of new
neurons from precursor cells. Imaging studies have shown
that girls with MECP2 mutations and RTT have an overall
reduction in brain volume compared with controls [37], but
there have been no reports of major neuropathological
abnormalities in girls with RTT. Instead, MECP2 mutations
seem to result in subtle changes in neuronal morphology.
Neuroanatomic studies demonstrate that specific popula-
tions of neurons from girls with RTT are smaller and have
reduced dendritic complexity than those found in control
samples, adding support to the idea that MeCP2 is involved
in neuronal maturation as opposed to formation. Although
MeCP2 expression is highest in neurons, glial cells have
detectable levels of MeCP2 expression as well. Recent
reports have suggested that MeCP2 expression in astrocytes
may be critical for RTT pathogenesis by disrupting support
for neuronal dendritic maturation [38•, 39•].
Murine models have been developed by targeted
disruption of Mecp2 that recapitulates many of the neuro-
developmental phenotypes seen in humans [40–42]. Defi-
ciency of MeCP2 specifically in postmitotic neurons is
responsible for the neurodevelopmental deficits in these
mice [40, 43]. Combined with the lack of major anatomic
defects in neurons lacking functional MeCP2, this suggests
that a lack of MeCP2 does not result in irreversible damage
to neurons. Instead, MeCP2 mutations may cause a
premature arrest in neuronal development with relative
sparing of neuronal commitment. Accordingly, reintroduc-
tion of functional MeCP2, even in symptomatic mice, can
rescue the developmental phenotypes associated with
MeCP2 deficiency [44•, 45••]. However, it is important to
note that overexpression of MeCP2 by even twofold can
cause related severe neurological defects [43, 46], indicat-
ing that levels of MeCP2 are tightly regulated and that too
little as well as too much functional MeCP2 can cause
neurodevelopmental disorders. The sensitivity of neurons to
aberrant levels of MeCP2 means that attempts to rescue
MeCP2 dysfunction in humans through reintroduction of a
functional MECP2 transgene will be challenging and
require a deeper understanding of MeCP2’s regulation and
mechanism(s) of action.
Molecular Mechanisms of Disease
Although much progress has been made in understanding the
functions of MeCP2 in recent years, it is still unclear exactly
how MECP2 mutations contribute to the pathogenesis of
RTT and related syndromes. The major anatomic differences
in brains of both girls with RTT and Mecp2-deficient mice
are reduced dendritic arborization and dendritic spine
formation, both of which are indicative of immature neurons
and would be predicted to represent a deficit in synaptic
formation and/or transmission. In support of this hypothesis,
it has been shown that brain samples from Mecp2-deficient
mice display reduced spontaneous synaptic transmission as
well as reduced synaptic plasticity—molecular processes that
underlie synaptic formation, learning, and memory [47].
Reduction of spontaneous transmission and synaptic plastic-
ity in these mice is a result of reduced synaptic connectivity
and a weakening of the remaining neuronal connections
caused by loss of Mecp2 [48•]. Synaptic deficits also have
been reported in transgenic mice with twofold Mecp2
overexpression [46], again demonstrating the strict require-
ments for regulation of MeCP2 levels in neuronal maturation.
Synapse formation and maturation requires activity-
dependent gene expression in neurons. Activation of an
immature neuron causes the induction of a large number of
genes that help strengthen and mature the developing
synapse. MeCP2 controls the expression of several of these
genes, including BDNF, ID1, EGR2,a n dJUNB. Activity–
dependent phosphorylation of MeCP2 is required for the
activity-dependent expression of BDNF [34] and proper
dendritic branching and dendritic spine formation in neurons.
Therefore, a loss of MeCP2-regulated, activity-dependent
gene expression may lead to the widespread deficiencies in
synaptic maturation observed in the brains of Mecp2-null
mice and girls with RTT. This in turn is thought to be the
underlying cause of RTT and other MeCP2-associated
neurodevelopmental disorders. The late-infancy onset of
RTT symptoms corresponds to the occurrence of elevated
MeCP2 levels in maturing neurons and fits with the predicted
Curr Psychiatry Rep (2010) 12:127–134 131role for MeCP2 in activity-dependent postnatal maturation of
neuronal synapses.
A large number of MECP2 mutations have been
reported, including point mutations that change single
amino acids in MeCP2, truncations that cause premature
termination that results in shortened MeCP2 protein, and
small deletions that are missing stretches of amino acids
from the interior of MeCP2. Mutations can be found
throughout the protein but tend to cluster in or include
regions that are important for MeCP2 functions. Through
mutation of critical amino acids or deletion of important
functional domains, MECP2 mutations result in a loss of
MeCP2 function. Mutant proteins show a reduced affinity
for methylated DNA and a reduced ability to regulate gene
expression [49]. Because of this, MeCP2 mutants cannot
properly regulate activity-dependent gene expression in
response to neuronal stimulation. Alternatively, MECP2
duplication or other mutations in noncoding regions of the
gene can lead to changes in MeCP2 expression levels and
do not change the intrinsic functions of the protein. Instead,
abnormal levels of MeCP2 will result in misregulation of
MeCP2 target genes. Both situations lead to improper
modulation of MeCP2-regulated pathways and result in
deficient neuronal maturation.
MECP2 mutations are involved in many different
disorders with substantial phenotypic overlap (Fig. 1). In
some instances, there is a clear segregation of specific
MECP2 mutations and particular disorders. MECP2 muta-
tions found in RTTare rarely seen in XLMR and vice versa.
This difference is due to the effects of different types of
mutations on MeCP2 function. Mutations found in XLMR
have a relatively mild effect on the biochemical functions
of MeCP2 when compared with those found in RTT [50].
This is likely to result in different patterns of neuronal
maturation and dysfunction, which will lead to different
phenotypic outcomes. However, a clear segregation be-
tween mutation type and symptoms is not always apparent.
Identical MECP2 mutations can be found in individuals
with many different diagnoses, ranging from classic RTT to
autism to AS. Even within RTT, a large phenotypic
variability exists between individuals with the same
MECP2 mutation. Some of this variability can be attributed
to differences in mutation type and XCI, but these alone
cannot explain all the variability seen in RTT. Much of this
variability across disorders and within RTT is likely due to
genetic modifiers—that is, variants of genes that are a part
of MeCP2-regulated pathways. On their own, variations in
these genes may not lead to visible phenotypes, but they
can affect the phenotypic outcome of MECP2 mutations. It
has been reported that a common polymorphism in the
BDNF gene found in healthy and affected individuals
correlates with increased severity and susceptibility to
seizures in RTT [51•]. Additional genetic modifiers likely
have yet to be identified, many of which may have no
apparent effect on their own but when combined with
mutations in MECP2 can lead to different neurodevelop-
mental phenotypes. Therefore, it is likely a complex
interaction between mutation type, XCI skewing (in the
case of females), and other genetic modifiers that leads to
the final phenotype in MECP2 mutations.
Conclusions
As is apparent by the spectrum and severity of associated
disorders, MeCP2 seems to be a critical regulator of neuronal
activity–dependent synaptic maturation. To achieve this,
MeCP2integratesepigeneticmarksandsignalsfromneuronal
activationtoregulatethe geneexpressionpatternsrequiredfor
neuronal maturation through long-range and local regulation
of chromatin structure. As such, MeCP2 occupies a central
role in the postnatal development of the human brain.
However, MeCP2 does not work in isolation. It is influenced
by and acts upon countless other genetic, epigenetic, and
environmental factors, all of which work in concert to insure
proper development of the human brain. Although each of
these MECP2-associated disorders is distinct, they share
significant phenotypic overlap, including core deficits in
cognition and motor function. A more complete understand-
ing of the molecular mechanisms surrounding MeCP2, as
well as the pathways in which it resides will not only
enhance our understanding of neuronal maturation but will
help us to understand the pathogenesis of multiple neuro-
developmental diseases. The relative sparing of neuronal
commitment in MECP2-related disorders provides hope that
potential therapies to restore MECP2 function or reactivate
MeCP2-dependent pathways may provide significant benefit
to individuals suffering from these disorders.
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